XML 91 R55.htm IDEA: XBRL DOCUMENT
v3.25.1

Segment information (Tables) | 12 Months Ended
--- | ---
Dec. 28, 2024
Segment Reporting [Abstract] |
Schedule of Segment Information | The following tables present our segment information (in $000’s):
| For the Years Ended
| December 28, 2024 |  | December 30, 2023
Revenue |  |  |
Fintech | $ | 12,532 |  |  | $ | — |
Biotech | — |  |  | — |
Corporate and other | — |  |  | — |
Discontinued operations | — |  |  | 3,795 |
Total Revenues | $ | 12,532 |  |  | $ | 3,795 |
Gross profit |  |  |
Fintech | $ | 6,294 |  |  | $ | — |
Biotech | — |  |  | — |
Corporate and other | — |  |  | — |
Discontinued operations | — |  |  | (197) |
Total Gross profit | $ | 6,294 |  |  | $ | (197) |
Operating loss |  |  |
Fintech | $ | 905 |  |  | $ | — |
Biotech | (2,148) |  |  | (1,531) |
Corporate and other | (6,319) |  |  | (18,315) |
Discontinued operations | — |  |  | 10,438 |
Total Operating loss | $ | (7,562) |  | $ | (7,562) |  | $ | (9,408) |
Depreciation and amortization |  |  |
Fintech | $ | 1,316 |  |  | $ | — |
Biotech | 2,086 |  |  | 1,452 |
Corporate and other | — |  |  | — |
Discontinued operations | — |  |  | 96 |
Total Depreciation and amortization | $ | 3,402 |  |  | $ | 1,548 |
Interest (expense) income, net |  |  |
Fintech | $ | (499) |  |  | $ | — |
Biotech | — |  |  | — |
Corporate and other | (380) |  |  | 2,250 |
Discontinued operations | — |  |  | (181) |
Total Interest (expense) income, net | $ | (879) |  |  | $ | 2,069 |
Net loss after provision for income taxes |  |  |
Fintech | $ | 469 |  |  | $ | — |
Biotech | (2,086) |  |  | (1,532) |
Corporate and other | (4,628) |  |  | (15,563) |
Discontinued operations | — |  |  | 9,283 |
Total net loss after provision for income taxes | $ | (6,245) |  |  | $ | (7,812) |
| As of December 28, 2024 |  | As of December 30, 2023
Assets |  |  |
Fintech | $ | 64,217 |  |  | $ | — |
Biotech | 16,926 |  |  | 17,846 |
Corporate and other | 1,293 |  |  | 641 |
Discontinue operations | — |  |  | — |
Total Assets | $ | 82,436 |  |  | $ | 18,487 |
Goodwill and other intangible Assets |  |  |
Fintech | $ | 30,385 |  |  | $ | — |
Biotech | 15,755 |  |  | 17,846 |
Corporate and other | 4 |  |  | — |
Discontinued operations | — |  |  | — |
Total goodwill and other intangible Assets | $ | 46,144 |  |  | $ | 17,846 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration